CLSD
Clearside Biomedical, Inc.NASDAQHealthcare$0.41+0.00%ClosedMarket Cap: $2.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.03
P/S
0.49
EV/EBITDA
-3.93
DCF Value
$-8.93
FCF Yield
-1336.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.6%
Operating Margin
-689.8%
Net Margin
-780.9%
ROE
55.5%
ROA
-223.3%
ROIC
-248.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $201.0K | 100.0% | $-7.0M | $-6.0M | $-1.14 | — |
| Q2 2025 | $492.0K | 82.9% | $-3.6M | $-4.5M | $-0.87 | — |
| Q1 2025 | $2.3M | 89.4% | $-5.2M | $-8.2M | $-1.65 | — |
| Q4 2024 | $306.0K | 51.3% | $-7.1M | $-7.3M | $-1.44 | — |
| FY 2024 | $1.7M | 91.0% | $-28.9M | $-34.4M | $-7.05 | — |
| Q3 2024 | $1.0M | 100.0% | $-5.9M | $-7.7M | $-1.50 | — |
| Q2 2024 | $90.0K | 100.0% | $-7.6M | $-7.6M | $-1.50 | — |
| Q1 2024 | $230.0K | 87.8% | $-8.2M | $-11.8M | $-2.55 | — |
| Q4 2023 | $6.3M | 99.7% | $-2.9M | $-4.8M | $-1.16 | — |
| FY 2023 | $8.2M | 95.7% | $-24.8M | $-32.5M | $-7.95 | — |
| Q3 2023 | $859.0K | 83.5% | $-7.1M | $-9.3M | $-2.25 | — |
| Q2 2023 | $1.0M | 79.1% | $-7.3M | $-9.1M | $-2.25 | — |